| Description of Skin Lesion/ Outcome |
Lenalidomide stopped permanently |
N/Sex/Age, y |
Disease |
Study Design |
Reference |
| Sweet Syndrome of the hands on day 6 after initiation of treatment with lenalidomide. Oral prednisolone 40mg was given and tapered over several weeks. |
yes |
1/M/57 |
MM |
Case Report |
Hoverson AR et al. 2006 |
| Granulomatous dermatitis on the trunk and extremities. The skin eruptions resolved. |
yes |
1/F/55 |
MM |
Case Report |
Deng A et al. 2006 |
| Neutrophilic dermatosis on day 14 after treatment initiation. Clinical improvement after discontinuation of lenalidomide and initiation of oral prednisolone. |
yes |
1/F/57 |
MM |
Case Report |
Thieu KP et al. 2009 |
| Acneiform lesions of the head and neck with the finding of Candida albicans at the end of the 3rd treatment cycle. Lesions resolved 3 months after lenalidomide cessation and treatment with topical desonide and oral doxycycline. |
yes |
1/M/75 |
MM |
Case Report |
Michot C et al. 2010 |
| Mildly pruritic truncal eruption within the 1st week after treatment initiation with lenalidomide for MM. Treatment was discontinued because of edema, fatigue, dizziness, gastritis and this skin eruption. 2 months later AM was diagnosed and a combination treatment with lenalidomide, dexamethasone, and melphalan begun. Purpuric skin eruptions appeared within 1 week of combination treatment. |
yes |
1/M/74 |
AM and MM |
Case Report |
Kuohung et al. 2011 |
| Blaschkitis along the left leg, the trunk and the left arm in the 4th month after treatment initiation. Disappearance of eruptions during drug-free intervals and reappearance after restart of treatment. |
no |
1/M/60 |
MM |
Case Report |
Grape J et al.. 2011 |
| Macular skin eruptions evolving to SJS after the end of the 1st treatment cycle. A symptomatic treatment with methylprednisolone, itraconazole, antihistamines and antiseptics was initiated. Skin lesions resolved after 30 days. |
yes |
1/F/69 |
MM |
Case Report |
Allegra A et al. 2012 |
| 3 patients developed skin reactions, 1 urticaria, 1 EM, 1 SJS. |
x |
2/F/70, 81
1/M/62 |
MM |
Case Reports |
Penna G et al. 2012 |
| SJS/TEN overlap appearing during the 2nd treatment cycle. Discontinuation of lenalidomide, systemic corticosteroids and intensive supportive care led to clinical recovery. |
yes |
1/M/61 |
MM |
Case Report |
Wäsch R et al.. 2012 |
| Skin eruptions progressing to SJS beginning on day 24 of the 1st treatment cycle. Progress of symptoms after initiation of prednisolone and antihistamines. Recovery under corticosteroids, high dose IVIG, prophylactic antibiotics and fluid input. |
yes |
1/M/51 |
PCL |
Case Report |
Siniscalchi A et al. 2012 |
| 12 reports of SJS, 3 reports of EM, 1 report of TEN. The median time of onset of event was 24 days (3-45) from start of lenalidomide. |
x |
7/F, 5/M
(median 63,5; 50-83) |
MM
MF
AM |
Case Reports from market launch 12/2005-06/2008) |
Castaneda CP et al. 2009 |
| Skin eruption were described as morbilliform (N=22), urticarial (N=6), dermatitic (N=2), acneiform (N=1) and undefined (N=1). |
x |
22/x/x
10/x/x |
MM
AM |
Retrospective review of medical records |
Sviggum HP et al. 2006 |
Abbreviations: AM: Amyloidosis; EM: Erythema Multiforme; F: Female; IVIG: Intravenous Immunoglobulins; M: Male; MF: Myelofibrosis; MM: Multiple Myeloma; N:
Number of Patients; PCL: Primary Plasma Cell Leukemia; SJS: Stevens-Johnson Syndrome; TEN: Toxic Epidermal Necrolysis; x: Not Listed; y: Years